Biota Pharmaceuticals, Inc. engages in the drug discovery and clinical development of anti-infectives in Australia. It offers zanamivir, a neuraminidase inhibitor for the treatment and prophylaxis of influenza; and laninamivir for the treatment of influenza. The company also provides influenza diagnostics test kits, such as BioStar OIA FLU, which detects influenza and assists the physician to differentiate influenza from other respiratory infections that may display similar symptoms; and Biostar OIA FLU A/B, a flu test that distinguishes between influenza A and B. In addition, it discovers, develops, and commercializes anti-infective products for the treatment of influenza, respiratory syncytial virus, human rhinovirus, and hepatitis C; and new classes of antibiotics to treat hospital-acquired and community-associated infections. The company was formerly known as Biota Holdings Limited and changed its name to Biota Pharmaceuticals, Inc. in October 2012. Biota Pharmaceuticals, Inc. was incorporated in 1985 and is based in Notting Hill, Australia.

Key Statistics